Norris Medicines Reports Positive Financial Results for Q1 2024 Despite 'Strong Sell' Rating
Norris Medicines, a microcap pharmaceutical company, reported a flat performance in the quarter ending March 2024 with a score of 3 out of 10. However, the company's profit before and after tax, as well as earnings per share, were the highest in the last five quarters, indicating a positive trend in the near term. MarketsMojo has given a 'Strong Sell' rating for the company's stock.
Norris Medicines, a microcap pharmaceutical company, has recently announced its financial results for the quarter ending March 2024. The company's stock has been given a 'Strong Sell' rating by MarketsMOJO.According to the financial report, Norris Medicines has shown a flat performance in the quarter, with a score of 3 out of 10. However, this is an improvement from the previous quarter's score of 0. The company's profit before tax, excluding other income, was the highest in the last five quarters at Rs 0.23 crore. This indicates a positive trend in the near term for the company's profitability.
Similarly, the company's profit after tax was also the highest in the last five quarters at Rs 0.17 crore, with a positive trend in the near term. The earnings per share for the quarter were also at their highest in the last five quarters, at Rs 0.17. This shows that Norris Medicines has been able to create higher earnings for its shareholders.
Overall, the financial results for the quarter ending March 2024 show positive trends for Norris Medicines. However, it is important to note that MarketsMOJO has given a 'Strong Sell' rating for the company's stock. Investors are advised to do their own research and make informed decisions before investing in the company.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
